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OBJECTIVE — Serine-threonine kinase STK11 catalyzes the AMP-activated protein kinase
complex.WetestedthehypothesisthatagenevariantinSTK11contributestovariationininsulin
sensitivity and metformin efﬁcacy.
RESEARCH DESIGN AND METHODS — We studied the effects of a single nucleotide
polymorphism (SNP) (rs8111699) in STK11 on endocrine-metabolic and body composition
indexes before and after 1 year of metformin in 85 hyperinsulinemic girls with androgen excess,
representingacontinuumfromprepuberalgirlswithacombinedhistoryoflowbirthweightand
precocious pubarche over to postmenarchial girls with hyperinsulinemic ovarian hyperandro-
genism. Metformin was dosed at 425 mg/day in younger girls and 850 mg/day in older girls.
STK11 rs8111699 was genotyped. Endocrine-metabolic features were assessed in the fasting
state; body composition was estimated by absorptiometry.
RESULTS — Genotype effects were similar in younger and older girls. At baseline, the
mutated G allele in STK11 rs8111699 was associated with higher insulin and IGF-I levels
(bothP  0.005).TheresponsetometformindifferedbySTK11genotype:GGhomozygotes
(n  24) had robust metabolic improvements, GC heterozygotes (n  38) had intermediate
responses, and CC homozygotes (n  23) had almost no response. Such differences were
found for 1-year changes in body composition, circulating insulin, IGF-I, free androgen
index, and lipids (all P  0.005).
CONCLUSIONS — In hyperinsulinemic girls with androgen excess, the STK11 rs8111699
SNPinﬂuencesinsulinsensitivityandmetforminefﬁcacy,sothatthegirlswiththeleastfavorable
endocrine-metabolic proﬁle improve most with metformin therapy.
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G
enetic variation in enzymes and
transporters mediating the actions
and metabolism of medications
contribute to interindividual variation in
therapeutic response, on the efﬁcacy as
well as on the safety side (1).
Polycystic ovary syndrome (PCOS) is
a common endocrinopathy that affects
5–10%ofyoungwomen;PCOSischar-
acterized by androgen excess plus either
anovulation or polycystic ovaries (2,3). A
majorityofpatientswithPCOSareinsulin
resistant, and, accordingly, metformin is
often prescribed for this condition, also
in adolescents (4,5). In selected girls at
high risk for developing hyperinsuline-
mic ovarian androgen excess, metformin
is even under exploration as a potentially
preventive treatment; among these high-
risk girls are those with a combined his-
tory of low birth weight (LBW) and
precocious pubarche (6–9).
The actions of metformin seem to be
largely exerted through activation of
AMP-activated protein kinase (AMPK), a
conserved regulator of the cellular re-
sponse to low energy, in many organs,
including liver and skeletal muscle (10,11).
The activation of AMPK in the liver is
catalyzed by serine-threonine kinase
(STK11, formerly known as LKB1), a tu-
mor suppressor gene defective in Peutz-
Jeghers syndrome (12); deletion of
hepatic STK11 in mice results in a nearly
completelossofAMPKactivity,leadingto
adipogenesis and lipogenic gene expres-
sion (13). STK11 serves as a mediator of
metformin effects, rather than as a direct
target of metformin (14).
Recently, the C allele of a single nucle-
otide polymorphism (SNP) (rs8111699) in
STK11hasbeenassociatedwithareduced
ovulatory response to metformin in
women with PCOS (15). In a pilot study,
we have tested the hypothesis that the
same SNP in STK11 also inﬂuences the
endocrine-metabolic and body composi-
tion changes after metformin therapy in
girls with hyperinsulinemic androgen
excess.
RESEARCH DESIGN AND
METHODS— The study population
consisted of 85 Caucasian, Northern
Spanishgirlsrepresentingacontinuumof
female subjects with hyperinsulinemic
androgen excess that commences in pre-
puberty in those girls with a combined
historyofLBWandprecociouspubarche,
is followed by a preclinical phase starting
around menarche of biochemical ovarian
hyperandrogenism and yields to an overt
clinical period of ovarian hyperandro-
genism2–3yearsaftermenarche.Allsub-
jects were included in similar clinical
trials investigating the safety and efﬁcacy
of metformin treatment on their hyperin-
sulinemic androgen excess.
The prepubertal girls (n  18; Tan-
ner stage I; aged 7.9  0.2 years; BMI
19.3  0.6 kg/m
2) had a combined a
history of LBW (2.3  0.1 kg at term
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Pediatrics, Dr. Josep Trueta Hospital, Girona, Spain; the
2Endocrinology Unit,
Hospital Sant Joan de De ´u, University of Barcelona, Barcelona, Spain; the
3Centro de Investigacio ´n
Biome ´dica en Red de Diabetes y Enfermedades Metabo ´licas Asociadas, Instituto de Salud Carlos III del
MinisteriodeCienciaeInnovacio ´n,Madrid,Spain;andthe
4DepartmentofWomanandChild,University
of Leuven, Leuven, Belgium.
Corresponding author: Lourdes Iba ´n ˜ez, libanez@hsjdbcn.org.
Received 18 September 2009 and accepted 18 March 2010. Published ahead of print at http://care.
diabetesjournals.org on 31 March 2010. DOI: 10.2337/dc09-1750.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Pathophysiology/Complications
ORIGINAL ARTICLE
1544 DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 care.diabetesjournals.orgbirth) and precocious pubarche (ap-
pearance of pubic hair before age 8
years) attributable to an exaggerated
adrenarche, based on high serum levels of
dehydroepiandrosterone sulfate or andro-
stenedione at diagnosis of precocious
pubarche (8). The girls were, in addition,
hyperinsulinemic, as judged by the in-
sulin response after an oral glucose tol-
erance test (16). All of these subjects
participated in a controlled long-term
study exploring the effects of early met-
formin treatment (ISRCTN84749320);
more speciﬁcally, they form together the
study subgroup that was initially ran-
domly assigned to receive metformin for
at least 1 year (425 mg, daily at dinner
time) (9).
The early postmenarcheal girls (n 
31; aged 12.2  0.1 years; BMI 21.5 
0.5 kg/m
2) manifested biochemical an-
drogenexcesscharacterizedastheensem-
ble of 1) absence of clinical signs or
symptoms of androgen excess (17) and2)
hyperinsulinemia (oral glucose tolerance
test) and 3) ovarian androgen excess sug-
gested by increased testosterone levels
and conﬁrmed by 17-hydroxyprogester-
one hyperresponse to gonadotropin-
releasing hormone agonist (17,18). The
girls in the present analysis were enrolled
in clinical studies that were initiated
before 2003, thus before compulsory
trial registration; as described, all these
girls had a history of LBW-precocious
pubarche and were already in the early
postmenarche phase (6–12 months be-
yond menarche) at start of metformin in-
tervention (8,19).
The adolescent girls (n  36; aged
15.5  0.3 years; BMI 21.9  0.5 kg/m
2)
were consecutive patients with PCOS
who were at least 2 years beyond men-
arche and who were followed in the
outpatient clinic according to standard
procedures, including yearly blood sam-
pling in the fasting state (once with DNA
extraction)andyearlyassessmentofbody
composition. The inclusion criteria were
the same as those for the early postmen-
archeal girls, except that the presence of
clinical markers of androgen excess
was now required: hirsutism (Ferriman-
Gallwey score 8) plus either amenor-
rhea (menses absent for 3 months) or
oligomenorrhea (menstrual cycle 45
days). In all postmenarcheal girls, base-
line assessments were performed in the
follicular phase (day 3–7) or after 2
months of amenorrhea.
All postmenarcheal girls received
metformin for at least 1 year in mono-
therapy(850mg,dailyatdinnertime).At
the start of metformin treatment, none of
the 85 girls presented evidence for thy-
roid dysfunction, Cushing syndrome, hy-
perprolactinemia, glucose intolerance, or
late-onset adrenal hyperplasia; for at least
6 months before the start of metformin
start, none of the girls received an estro-
progestagen or other medication known
toaffectgonadalfunctionorcarbohydrate
metabolism.
Clinical, endocrine, and metabolic
assessments
Height and weight were measured, and
BMI was calculated (weight in kilograms
dividedbythesquareofheightinmeters).
BMI standard deviation scores (SDSs)
were derived from regional normative
data (20).
Fasting blood glucose, serum insu-
lin, IGF-I, sex hormone–binding glob-
ulin (SHBG), and testosterone were
measured as described previously (9).
Free androgen index was calculated as
testosterone  100/SHBG. Serum lipids
were measured by routine laboratory
methods.
Genetic analysis
Genomic DNA was puriﬁed from whole
blood samples using commercial re-
agents (Gentra Puragene Cell Kit; Qia-
gen Iberia, Madrid, Spain). The STK11
rs8111699 SNP was genotyped by a ﬂu-
orescent genotyping system (KASPar
SNP Genotyping System; KBiosciences,
Hoddesdon, U.K.). In brief, 10 pg
genomic DNA was incubated in a 8-l
solution of a combined mix containing
100 mol/l allele speciﬁc primer 1 (FAM,
x-axis, allele G), 5-GAAGGTGAC
CAAGTTCATGCTCCACTGACTGT
TCAGGAAAGCAC-3, 100 mol/l allele-
speciﬁc primer 2 (VIC, y-axis, allele C),
5-GAAGGTCGGAGTCAACGGATTC
CACTGACTGTTCAGGAAAGCAG-3,
100 mol/l common reverse primer 5-
GGTGGAAGCCTGACTGTGAGAGT-
3, 10 mol/l Tris-HCl, pH 8.3, KTaq
polymerase, 1.8 mmol/l MgCl2, and
ROX as a passive reference. The PCR
mix was incubated at 94°C for 15 min,
followed by 20 cycles of 94°C for 10 s,
57°C for 5 s, and 72°C for 10 s. There-
after, the PCR mix was incubated for 18
cycles at 94°C for 10 s, 57°C for 20 s,
and 72°C for 40 s. Samples were then
read in a ﬂuorescence plate reader. The
KASPar system uses the ﬂuors FAM and
VIC for distinguishing among geno-
types and ROX as a passive reference.
The corresponding genotypes for this
SNP (CC vs. CG vs. GG) did not differ
among prepuberty (33% vs. 44% vs.
22%), early postmenarche (26% vs.
49% vs. 26%), and PCOS (25% vs. 42%
vs. 33%) subjects in our study (P 
0.89). The distributions were also
tested for Hardy-Weinberg equilib-
rium, and none deviated signiﬁcantly.
Body composition
Body composition was assessed by dual-
energyX-rayabsorptiometrywithaLunar
Prodigy and Lunar software (version 3.4/
3.5; Lunar, Madison, WI) (9). Total irra-
diation dose per assessment was 0.1
mSevert;coefﬁcientsofvariationforscan-
ning precision are 2.2 and 2.6% for fat
and lean mass (8,9,19).
Ethics and statistics
Thestudyprotocolwasapprovedbythe
Institutional Review Board of Hospital
of Sant Joan de De ´u. Informed consent
was obtained from the patients and/or
from parents, and assent was obtained
from girls, as appropriate. The clinical,
biochemical, and body composition
data from prepubertal and early post-
menarchealsubjectshavebeenreported
separately (8,9,19). Statistical analyses
were performed using SPSS (version
12.0; SPSS, Chicago, IL). Quantitative
phenotypic data were compared across
genotypes by a repeated-measures gen-
eral linear model, computing the geno-
type as the between-subjects effect and
both baseline and 1-year values as the
within-subjects effect. Differences in
1-year changes across genotypes were
tested by the interaction term among
the between- and within-subjects ef-
fects. P  0.05 was considered statisti-
cally signiﬁcant.
RESULTS— Clinical and laboratory
characteristics of the study subjects are
shown in Table 1. Genotype effects were
similar in prepubertal, early postmenar-
cheal, and PCOS subjects, and therefore
genotype-phenotypeassociationsarepre-
sented for all 85 girls studied as a single
group (adjusted for group allocation) to
maximize the statistical power.
At diagnosis, the G allele in STK11
rs8111699 was associated with a poorer
metabolic proﬁle, speciﬁcally with higher
insulinandIGF-I(bothP0.005)(Table
2). The presence of this allele was at
baseline unrelated to age, weight, body
composition parameters, and serum an-
drogens and lipids (Table 2).
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pronounced differences in the response
to metformin according to the STK11
rs8111699 genotype, as reﬂected by a
robust response in the main endocrine-
metabolic and body composition pa-
rameters in GG homozygotes, with an
intermediate response in CG heterozy-
gotes and almost no response in CC ho-
mozygotes (Table 2). Such differences
were found for 1-year changes in body
composition, circulating insulin, IGF-I,
free androgen index, and lipids (all P 
0.005; Table 2). All of these compari-
sons were adjusted for differences in
baseline insulin levels.
CONCLUSIONS — Our results in-
dicate that the STK11 rs8111699 SNP
inﬂuences both insulin sensitivity and
metformin efﬁcacy in hyperinsulinemic
girls with androgen excess. Despite the
fact that neither STK11 nor AMPK is a
directtargetofmetformin(14),bothare
necessary for metformin actions (14). It
has been proposed that STK11 is con-
stitutivelyactiveandthatmetforminex-
erts its hypoglycemic effects through a
modiﬁcation in AMPK, rendering it a
better substrate for STK11 (10). Al-
though the role of the studied intronic
SNP in STK11 has yet to be deﬁned, it is
known that intronic SNPs may regulate
gene expression and alternative splicing
(21). The STK11 rs8111699 SNP may
also be in linkage disequilibrium with
an active SNP in the kinase gene region.
The STK11 rs8111699 SNP was asso-
ciated with baseline insulin sensitivity in
girls with hyperinsulinemic androgen ex-
cess. Bearing in mind that STK11 may be
constitutively active, we postulate that
carrying the G allele in the STK11
rs8111699 SNP can result in lower
STK11 activity and therefore lower efﬁ-
ciency of AMPK phosphorylation by
STK11.
The same G allele in the STK11
rs8111699 SNP was associated with
pronounced changes in endocrine-
metabolic and body composition pa-
rameters upon metformin treatment,
effects that were nearly absent in C ho-
mozygous subjects. We suggest that
metformin restores the efﬁciency of
AMPK phosphorylation by STK11 in
carriers of the G allele and has less or no
effect in the absence of such allele. Our
observationsconcurwiththoseofLegro
et al. (15), who found a stepwise in-
creaseinovulationratefromC/CtoC/G
to G/G genotype in women with PCOS
treated with metformin.
AMPKisanindirecttargetofanum-
ber of drugs besides metformin. These
include the commonly used thiazoli-
dinediones and statins (22). The STK11
rs8111699 SNP may thus play a broader
role in metabolic and cardiovascular dis-
eases by modulating the baseline condi-
tion as well as the response to treatment
with the above-mentioned pharmacolog-
ical agents.
A limitation of our study is the in-
sufﬁcient power to analyze the effect of
the STK11 SNP in each of the three sub-
groups within the total study popula-
tion. Such an analysis would have been
of interest because each of the consecu-
tive subgroups is thought to represent a
developmental stage of hyperinsuline-
mic androgen excess. It should be
noted, however, that the results re-
mained essentially the same with and
without adjustment for subgroup allo-
cation in the multivariate model.
Hyperinsulinemic androgen excess is
aratherheterogeneouscondition(3).The
identiﬁcation of genetic polymorphisms
that contribute to predict the response to
commonly prescribed medications
should assist clinicians in their selection
Table 1—Clinical, biochemical, and body composition variables before and after 1 year of metformin in the study subjects
All Prepubertal Early postmenarcheal PCOS
Baseline
1 year of
metformin Baseline
1 year of
metformin Baseline
1 year of
metformin Baseline
1 year of
metformin
n 85 85 18 18 31 31 36 36
Age (years) 12.6  0.3 — 7.9  0.2 — 12.2  0.1 — 15.5  0.3 —
BMI (kg/m
2) 21.2  0.3 21.4  0.3 19.3  0.6 19.7  0.6 21.5  0.5 21.7  0.5 21.9  0.5 22.0  0.5
BMI SDS 0.8  0.1 0.9  1.1 1.5  0.3 1.5  0.4 0.6  0.3 0.7  0.4 0.8  0.3 0.8  0.2
Glucose (mg/dl) 88  18 8  18 8  29 1  28 9  19 0  18 7  18 6  1
Insulin (mIU/l) 12.7  0.5 9.9  0.4† 9.6  1.1 9.3  0.9 13.2  0.7 10.4  0.7* 13.8  0.9 9.8  0.7†
IGF-I (ng/ml) 286  10 254  7† 200  17 219  12 342  17 283  13† 287  10 245  7*
SHBG (g/dl) 1.1  0.1 1.3  0.1† 1.3  0.1 1.5  0.1* 1.1  0.1 1.3  0.1* 1.0  0.1 1.2  0.1†
Testosterone (ng/dl) 73  55 2  3† 35  43 0  47 1  55 2  3† 94  86 2  4†
Free androgen index 8.7  0.8 4.6  0.3† 3.3  0.4 2.5  0.4* 8.1  0.9 4.7  0.4† 12.0  1.6 5.6  0.6†
Triglycerides (mg/dl) 79  46 4  3† 77  12 70  11 75  56 2  3† 82  66 2  4*
LDL cholesterol (mg/dl) 99  38 9  2† 107  89 4  59 3  48 7  3 101  48 9  4*
HDL cholesterol (mg/dl) 56  16 2  1† 57  36 0  35 3  25 9  2* 57  26 6  2†
LDL cholesterol-to-HDL
cholesterol ratio 1.9  0.1 1.5  0.1† 2.0  0.2 1.7  0.1 1.8  0.1 1.5  0.1 1.8  0.1 1.4  0.1†
Fat mass (kg) 17.1  0.8 16.8  0.8 11.4  0.9 12.2  1.0 17.7  1.2 17.5  1.2 19.5  1.3 18.9  1.3*
Abdominal fat (kg) 5.1  0.3 4.7  0.3† 3.5  0.4 3.5  0.4 4.8  0.4 4.5  0.3 6.2  0.5 5.5  0.5†
Lean mass (kg) 31.2  0.7 33.0  0.7† 21.2  0.8 23.9  0.9† 33.2  0.7 35.0  0.6† 34.5  0.7 35.9  0.7†
ValuesaremeansSEM.ValuesinhealthygirlsmatchedforBMI:prepubertal(n24;aged8.30.3years):insulin6.50.5mIU/l,IGF-I20015ng/ml,SHBG
3.6  0.1 g/dl, testosterone 16  2 ng/dl; pubertal (n  24; age 15.3  0.2 years): insulin 8.8  0.4 mIU/l, IGF-I 384  26 ng/ml, SHBG 1.9  0.1 g/dl,
testosterone 31  3 ng/dl. Lipid proﬁle: triglycerides 55  4 mg/dl; LDL 83  3 mg/dl; HDL 65  2 mg/dl (8,23 and Ibáñez et al.; JCEM 2004; 89:4,331–337). P
values are from paired-samples Student t-test. *P  0.005; †P  0.0001.
STK11 and metformin efﬁcacy
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ment, thereby improving the therapeutic
response, both on the efﬁcacy and on the
safety side.
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